Literature DB >> 25905694

Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.

Gemma Di Pompo1,2, Manuela Salerno1,2, Dante Rotili3, Sergio Valente3, Clemens Zwergel3, Sofia Avnet1, Giovanna Lattanzi4, Nicola Baldini1,2, Antonello Mai3,5.   

Abstract

Musculoskeletal sarcomas are aggressive malignancies of bone and soft tissues often affecting children and adolescents. Histone deacetylase inhibitors (HDACi) have been proposed to counteract cancer stem cells (CSCs) in solid neoplasms. When tested in human osteosarcoma, rhabdomyosarcoma, and Ewing's sarcoma stem cells, the new HDACi MC1742 (1) and MC2625 (2) increased acetyl-H3 and acetyl-tubulin levels and inhibited CSC growth by apoptosis induction. At nontoxic doses, 1 promoted osteogenic differentiation. Further investigation with 1 will be done in preclinical sarcoma models.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25905694     DOI： 10.1021/acs.jmedchem.5b00126

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  20 in total

Review 1.  Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Authors:  Fan Tang; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2017-07-06       Impact factor: 12.111

2.  Effects of Structurally Different HDAC Inhibitors against Trypanosoma cruzi, Leishmania, and Schistosoma mansoni.

Authors:  Elisabetta Di Bello; Beatrice Noce; Rossella Fioravanti; Clemens Zwergel; Sergio Valente; Dante Rotili; Giulia Fianco; Daniela Trisciuoglio; Marina M Mourão; Policarpo Sales; Suzanne Lamotte; Eric Prina; Gerald F Späth; Cécile Häberli; Jennifer Keiser; Antonello Mai
Journal:  ACS Infect Dis       Date:  2022-06-22       Impact factor: 5.578

3.  Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells.

Authors:  Tokuhiro Chano; Sofia Avnet; Katsuyuki Kusuzaki; Gloria Bonuccelli; Pierre Sonveaux; Dante Rotili; Antonello Mai; Nicola Baldini
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

4.  Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer.

Authors:  Eriko Yokoi; Seiji Mabuchi; Kotaro Shimura; Naoko Komura; Katsumi Kozasa; Hiromasa Kuroda; Ryoko Takahashi; Tomoyuki Sasano; Mahiru Kawano; Yuri Matsumoto; Michiko Kodama; Kae Hashimoto; Kenjiro Sawada; Tadashi Kimura
Journal:  Invest New Drugs       Date:  2018-10-30       Impact factor: 3.850

5.  Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy.

Authors:  Fengkun Lu; Lei Hou; Sizhen Wang; Yingjie Yu; Yunchang Zhang; Linhong Sun; Chen Wang; Zhiqiang Ma; Feng Yang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

6.  Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells.

Authors:  Marta Di Martile; Marianna Desideri; Teresa De Luca; Chiara Gabellini; Simonetta Buglioni; Adriana Eramo; Giovanni Sette; Michele Milella; Dante Rotili; Antonello Mai; Simone Carradori; Daniela Secci; Ruggero De Maria; Donatella Del Bufalo; Daniela Trisciuoglio
Journal:  Oncotarget       Date:  2016-03-08

Review 7.  Overcoming Therapeutic Resistance of Bone Sarcomas: Overview of the Molecular Mechanisms and Therapeutic Targets for Bone Sarcoma Stem Cells.

Authors:  Tomohiro Fujiwara; Toshifumi Ozaki
Journal:  Stem Cells Int       Date:  2016-12-27       Impact factor: 5.443

Review 8.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

Review 9.  Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance.

Authors:  Saeedeh Keyvani-Ghamsari; Khatereh Khorsandi; Azhar Rasul; Muhammad Khatir Zaman
Journal:  Clin Epigenetics       Date:  2021-05-29       Impact factor: 6.551

Review 10.  Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.

Authors:  Ander Abarrategi; Juan Tornin; Lucia Martinez-Cruzado; Ashley Hamilton; Enrique Martinez-Campos; Juan P Rodrigo; M Victoria González; Nicola Baldini; Javier Garcia-Castro; Rene Rodriguez
Journal:  Stem Cells Int       Date:  2016-06-05       Impact factor: 5.443
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.